Allena Pharmaceuticals Initial Public Offering
11/6/2017

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross proceeds of approximately $75 million. Allena Pharmaceuticals’ common stock is traded on the NASDAQ Global Select Market under the symbol “ALNA.” 

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. 

The Davis Polk corporate team included partners Sophia Hudson and Joseph A. Hall and associates Cameron C. Lewis and Yoojin L. Kim. Counsel David R. Bauer and associate Carrie Guo provided intellectual property and technology advice. Partner Mary Conway and associate K. Daniel Berman provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.